94 related articles for article (PubMed ID: 31838207)
1. A polyphenol-metal nanoparticle platform for tunable release of liraglutide to improve blood glycemic control and reduce cardiovascular complications in a mouse model of type II diabetes.
He Z; Nie T; Hu Y; Zhou Y; Zhu J; Liu Z; Liu L; Leong KW; Chen Y; Mao HQ
J Control Release; 2020 Feb; 318():86-97. PubMed ID: 31838207
[TBL] [Abstract][Full Text] [Related]
2. Sustained release of exendin-4 from tannic acid/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes.
He Z; Hu Y; Gui Z; Zhou Y; Nie T; Zhu J; Liu Z; Chen K; Liu L; Leong KW; Cao P; Chen Y; Mao HQ
J Control Release; 2019 May; 301():119-128. PubMed ID: 30894322
[TBL] [Abstract][Full Text] [Related]
3. Kinetic control of Phytic acid/Lixisenatide/Fe (III) ternary nanoparticles assembly process for sustained peptide release.
Wang Y; Song X; Zhuang L; Lang H; Yu L; Yan X; He Z
Int J Pharm; 2022 Jan; 611():121317. PubMed ID: 34838624
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
5. GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols.
Kaneko S; Ueda Y; Tahara Y
Eur Surg Res; 2018; 59(5-6):349-360. PubMed ID: 30537714
[TBL] [Abstract][Full Text] [Related]
6. A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges.
King AB; Philis-Tsimikas A; Kilpatrick ES; Langbakke IH; Begtrup K; Vilsbøll T
Diabetes Technol Ther; 2017 Apr; 19(4):255-264. PubMed ID: 28282219
[TBL] [Abstract][Full Text] [Related]
7. Development of 1 Month Sustained-Release Microspheres Containing Liraglutide for Type 2 Diabetes Treatment.
Gao Z; Wei Y; Ge J; Liu J; Qin Y; Gong F; Ma G
ACS Appl Mater Interfaces; 2024 May; 16(20):25869-25878. PubMed ID: 38728411
[TBL] [Abstract][Full Text] [Related]
8. Prolonged melittin release from polyelectrolyte-based nanocomplexes decreases acute toxicity and improves blood glycemic control in a mouse model of type II diabetes.
Gui Z; Zhu J; Ye S; Ye J; Chen J; Ling Y; Cai X; Cao P; He Z; Hu C
Int J Pharm; 2020 Mar; 577():119071. PubMed ID: 31991184
[TBL] [Abstract][Full Text] [Related]
9. Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.
Li Y; Zheng J; Shen Y; Li W; Liu M; Wang J; Zhu S; Wu M
Med Sci Monit; 2018 May; 24():3293-3300. PubMed ID: 29777582
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients.
Madsbad S
Expert Rev Cardiovasc Ther; 2019 May; 17(5):377-387. PubMed ID: 31055989
[No Abstract] [Full Text] [Related]
11. Liraglutide: a new treatment for type 2 diabetes.
Vilsboll T
Drugs Today (Barc); 2009 Feb; 45(2):101-13. PubMed ID: 19343230
[TBL] [Abstract][Full Text] [Related]
12. Liraglutide Improves Glycemic and Blood Pressure Control and Ameliorates Progression of Left Ventricular Hypertrophy in Patients with Type 2 Diabetes Mellitus on Peritoneal Dialysis.
Hiramatsu T; Ozeki A; Asai K; Saka M; Hobo A; Furuta S
Ther Apher Dial; 2015 Dec; 19(6):598-605. PubMed ID: 26556397
[TBL] [Abstract][Full Text] [Related]
13. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.
Degn KB; Juhl CB; Sturis J; Jakobsen G; Brock B; Chandramouli V; Rungby J; Landau BR; Schmitz O
Diabetes; 2004 May; 53(5):1187-94. PubMed ID: 15111485
[TBL] [Abstract][Full Text] [Related]
14. [The extra-glycemic effects of liraglutide: focus on cardiometabolic markers].
Giglio RV; Patti AM; Nikolic D; Castellino G; Noto M; Parrino A; Montalto G; Rizzo M
G Ital Cardiol (Rome); 2016 Apr; 17(4):253-8. PubMed ID: 27093208
[TBL] [Abstract][Full Text] [Related]
15. Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes.
Harris S; Abrahamson MJ; Ceriello A; Charpentier G; Evans M; Lehmann R; Liebl A; Linjawi S; Holt RIG; Hosszúfalusi N; Rutten G; Vilsbøll T
Drugs; 2020 Feb; 80(2):147-165. PubMed ID: 31960258
[TBL] [Abstract][Full Text] [Related]
16. Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
Vedtofte L; Knop FK; Vilsbøll T
Expert Rev Clin Pharmacol; 2015 May; 8(3):273-82. PubMed ID: 25816888
[TBL] [Abstract][Full Text] [Related]
17. Management of Diabetes Mellitus With Glucagonlike Peptide-1 Agonist Liraglutide in Renal Transplant Recipients: A Retrospective Study.
Liou JH; Liu YM; Chen CH
Transplant Proc; 2018 Oct; 50(8):2502-2505. PubMed ID: 30316386
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review.
Yousef CC; Thomas A; Matar MA; Ghandoura L; Aldossary I; Almuhanna SM; Alhussain F; Al Bisher FB; Aljohani RM; Balubaid AN; Nouh MI; Almurashi A; AlAmoudi R
Diabetes Res Clin Pract; 2021 Jul; 177():108871. PubMed ID: 34052248
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.
Vedtofte L; Knop FK; Vilsbøll T
Expert Opin Drug Saf; 2017 Mar; 16(3):387-396. PubMed ID: 28150516
[TBL] [Abstract][Full Text] [Related]
20. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Dempsey M; Mocarski M; Langer J; Hunt B
Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
